Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A1 + MAGE-A3 + NY-ESO-1 Vaccine
- Development stage
- Phase 1
- Lead developer
- Cancer Research UK
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
The MAGE-A1 + MAGE-A3 + NY-ESO-1 Vaccine is an investigational cancer vaccine composed of overlapping peptides derived from the full-length tumor-associated antigens (TAAs) MAGE-A1, MAGE-A3, and NY-ESO-1. These antigens are commonly overexpressed in a variety of solid tumors. The vaccine is typically administered using autologous dendritic cells pulsed with these peptides to stimulate an antigen-specific immune response against cancer cells expressing these TAAs. The mechanism involves priming the patient’s immune system—particularly T cells—to recognize and attack tumor cells displaying these antigens. This approach has been studied primarily in pediatric patients with relapsed or refractory solid tumors such as neuroblastoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma[2][6][3]. Clinical trials have demonstrated feasibility and tolerability for this regimen when combined with agents like decitabine to enhance antigen expression on tumor cells[2][7].
- Other names
- MAGE-A1, MAGE-A3, and NY-ESO-1 peptides vaccine
02
Targets
MAGEA1 (Melanoma-associated antigen 1)MAGEA3 (Melanoma-associated antigen 3)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on MAGE-A1 + MAGE-A3 + NY-ESO-1 Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A1 + MAGE-A3 + NY-ESO-1 Vaccine.